Characterization of the primary antibody response to Plasmodium falciparum antigens in infants living in a malaria-endemic area

Table 2 Characteristics of maternal IgG transplacentally transferred to babies

	Amount of Ab MFI at day 9 ± 2 (median, 1st, 3rd quartile)	Percentage of Ab-positive Babies^a	Ab Half-life, ± 95% CI (months)^b	Length of detectable maternal IgG (months)
AMA1 (3D7)	11,757 (8,765, 14,108)	96.9	1.46 (1.17, 1.94)	6
AMA1 (FVO)	12,581 (10,218, 14,870)	96.9	1.88 (1.4, 2.59)	8
EBA-175	10,800 (3,635, 12,460)	79.7	0.98 (0.83,1.21)	6
MSP1-42 (3D7)	1,003 (10, 3,868)	35.9	NC^c	NC
MSP1-42 (FVO)	4,637 (615, 11,207)	67.2	NC	3
MSP2 (3D7)	6,235 (2,298, 10,163)	76.6	0.78 (0.67, 0.92)	3
MSP2 (FC27)	6,935 (2,325, 10,163)	81.3	0.73 (0.64, 0.86)	NC
MSP3	239 (0, 1,482)	31.3	2.41 (1.58, 5.04)	NC
RESA	0 (0, 0)	0	NC	NC
LSA-1	0 (0, 218)	23.4	NC	NC
CSP	0 (0, 352)	25.0	2.39 (1.64, 4.36)	NC

^aPercent of babies at 9 ± 2 days with MFI above cut-off: AMA1(3D7) 1,970 MFI; AMA1 (FVO) 2,050 MFI; EBA-175 (2,020 MFI; MSP1(3D7) 1,500MFI; MSP1(FVO) 1,800 MFI; MSP2(3D7) 1,980 MFI; MSP2(FC27) 1,880 MFI; MSP3 842 MFI; RESA 390 MFI; LSA-1 380 MFI; CSP 490 MFI
^bbased on IgG Ab levels between Day 9 ± 2 after birth until 6 months of age
^cNot calculatable, because no consistent decline occurred or Ab were produced prior to 6 months

ISSN: 1475-2875